Mexico and Brazil do not plan to limit access to AstraZeneca’s COVID-19 vaccine after the UK drug regulator recommended doing so amid a potential risk of blood clots.
The statements come after the UK Health Products and Medicines Regulatory Agency (MHRA) recommended that the vaccine is only used in people over 30 years of age due to the possible link with rare blood clots.
The agency said it reviewed 79 reports of rare blood clots after the vaccine was administered, with 19 deaths. Eleven of the 19 who died were under 50, while three were under 30.
Mexico’s drug regulator Cofepris said it is still reviewing the recommendations. However, “it does not plan to limit the use of AstraZeneca vaccines to any age or group,” Reuters reported. Mexico has acquired 3.5 million doses of the vaccine so far.
Meanwhile, the Brazilian health regulatory agency, Anvisa, said the vaccine’s benefits outweighed the risk and recommended its continued use. The media reported that Brazil administered more than 4 million injections of the vaccine and recorded only 47 coagulation events.
The UK recommendation came on the same day that the European Medicines Agency (EMA) safety panel concluded that “possible link”Between rare blood clots and the vaccine existed.
Concern over the formation of blood clots in a small number of patients has resulted in the suspension of vaccine use by more than a dozen countries last month. Oxford University paused a clinical trial testing the vaccine on 300 children aged 6 to 17, while waiting for the MHRA’s opinion on blood clotting reports.
AstraZeneca said its evidence found no causal link between its vaccine and blood clotting.